We are live on ! Find out more
PCM

Parsons Capital Management Portfolio holdings

AUM $2.21B
1-Year Est. Return 28.12%
This Fund
S&P 500
This Quarter Est. Return
+12.76%
1 Year Est. Return
+28.12%
3 Year Est. Return
+84.89%
5 Year Est. Return
+106.02%
10 Year Est. Return
+446.13%
AUM
$996M
AUM Growth
+$73M
Cap. Flow
-$4.39M
Cap. Flow %
-0.44%
Top 10 Hldgs %
32.34%
Holding
361
New
17
Increased
88
Reduced
159
Closed
12

Top Buys

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$11.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$3.4M
3
TFC icon
Truist Financial
TFC
+$2.17M
4
FENY icon
Fidelity MSCI Energy Index ETF
FENY
+$1.55M
5
IBM icon
IBM
IBM
+$1.33M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$6.06M
2
MMM icon
3M
MMM
+$6.04M
3
STI
SunTrust Banks, Inc.
STI
+$2.12M
4
STZ icon
Constellation Brands
STZ
+$1.69M
5
XLE icon
State Street Energy Select Sector SPDR ETF
XLE
+$1.45M

Sector Composition

Rank Sector Weight
1 Technology 19.34%
2 Healthcare 13.59%
3 Financials 12.59%
4 Industrials 12.28%
5 Consumer Discretionary 6.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DLTR icon
326
Dollar Tree
DLTR
$25.2B
$221K 0.02%
2,349
-125
-5% -$13.1K
DHI icon
327
D.R. Horton
DHI
$42.3B
$219K 0.02%
4,158
– –
GSK icon
328
GSK
GSK
$106B
$218K 0.02%
+3,718
New +$207K
HPF
329
John Hancock Preferred Income Fund II
HPF
$345M
$215K 0.02%
9,648
-2
-0% -$44
AB icon
330
AllianceBernstein
AB
$3.47B
$209K 0.02%
6,900
-500
-7% -$14.6K
HAS icon
331
Hasbro
HAS
$13.2B
$209K 0.02%
1,975
– –
ROK icon
332
Rockwell Automation
ROK
$49B
$208K 0.02%
1,025
-225
-18% -$41.7K
KHC icon
333
Kraft Heinz
KHC
$30B
$206K 0.02%
+6,424
New +$195K
GDX icon
334
VanEck Gold Miners ETF
GDX
$27.4B
$205K 0.02%
+7,000
New +$191K
FDS icon
335
Factset
FDS
$10.2B
$201K 0.02%
+750
New +$193K
ET icon
336
Energy Transfer Partners
ET
$69.3B
$154K 0.02%
12,024
-544
-4% -$6.7K
FCX icon
337
Freeport-McMoran
FCX
$97.5B
$149K 0.02%
11,387
-2,013
-15% -$22.1K
FSTX
338
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$147K 0.01%
23,185
-45,381
-66% -$577K
CLPT icon
339
ClearPoint Neuro
CLPT
$433M
$128K 0.01%
26,623
– –
AXU
340
DELISTED
Alexco Resource Corp
AXU
$104K 0.01%
45,000
+30,000
+200% +$55.3K
JNCE
341
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$94K 0.01%
10,816
– –
DALN
342
DELISTED
DallasNews
DALN
$85K 0.01%
7,500
– –
LIQT icon
343
LiqTech
LIQT
$21M
$70K 0.01%
1,500
– –
TGEN
344
Tecogen Inc
TGEN
$116M
$52K 0.01%
24,369
– –
VSTM icon
345
Verastem
VSTM
$610M
$17K ﹤0.01%
1,065
– –
CFMS
346
DELISTED
Conformis, Inc. Common Stock
CFMS
$17K ﹤0.01%
440
– –
CHK
347
DELISTED
Chesapeake Energy Corporation
CHK
$9K ﹤0.01%
53
-22
-29% -$4.42K
DVLT
348
Datavault AI
DVLT
$263M
– –
0
– –
CPHI icon
349
China Pharma Holdings
CPHI
$45.8M
$2K ﹤0.01%
20
– –
BCX icon
350
BlackRock Resources & Commodities Strategy Trust
BCX
$923M
– –
-16,500
Closed -$123K
11 12 13
14
15

Similar funds

WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
IFA
Index Fund Advisors Irvine, California $2.22B AUM 20.66% 1-Year Est. Return
DPCM
Darlington Partners Capital Management Greenbrae, California $2.23B AUM 16.2% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.23B AUM 15.01% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
ORCP
One Rock Capital Partners New York $2.19B AUM
NP
NS Partners London, United Kingdom $2.23B AUM 20.03% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $2.23B AUM 12.38% 1-Year Est. Return

Parsons Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Parsons Capital Management held 361 positions worth $996M, up 7.9% from $923M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Parsons Capital Management's Q4 2019 filing shows 17 new, 88 increased, 159 reduced and 12 closed positions. Its largest new stake was Relmada Therapeutics: 366,933 shares worth $14.3M. The largest sale was Celgene Corp, an estimated $6.06M.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.

  • Parsons Capital Management's largest Q4 2019 buy was Relmada Therapeutics: 366,933 shares worth $14.3M.
  • Parsons Capital Management added most to Bristol-Myers Squibb in Q4 2019, an estimated $3.4M increase.
  • Parsons Capital Management's biggest Q4 2019 reduction was 3M, cutting an estimated $6.04M.
  • Parsons Capital Management fully exited Celgene Corp in Q4 2019, selling an estimated $6.06M.
  • Parsons Capital Management's ten largest holdings make up 32% of its $996M portfolio in Q4 2019.
  • Parsons Capital Management opened 17 new positions and closed 12 in Q4 2019.
  • Parsons Capital Management's portfolio value rose 7.9% quarter-over-quarter to $996M.

Based on Parsons Capital Management's 13F filing for Q4 2019, filed 3 Feb 2020.